Mannkind (MNKD) Total Non-Current Liabilities (2012 - 2026)
Mannkind (MNKD) reported Total Non-Current Liabilities of $798.5 million for Q1 2026, down 4.73% quarter-over-quarter from $838.1 million in Q4 2025.
Mannkind (MNKD) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Mannkind (MNKD) has 15 years of Total Non-Current Liabilities data on file, last reported at $798.5 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $798.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $798.5 million (changed N/A YoY), and the FY2025 annual result was $838.1 million, changed N/A from the prior year.
- Total Non-Current Liabilities fell to $798.5 million in Q1 2026 per MNKD's latest filing, from $838.1 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $838.1 million in Q4 2025 and troughed at -$55000.0 in Q4 2022.
- A 5-year average of $526.4 million and a median of $553.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities slumped 100.01% in 2022, then jumped 265107.27% in 2023.
- A 5-year view of Total Non-Current Liabilities shows it stood at -$55000.0 in 2022, then jumped by 265107.27% to $145.8 million in 2023, then soared by 387.67% to $710.8 million in 2024, then increased by 17.91% to $838.1 million in 2025, then fell by 4.73% to $798.5 million in 2026.
- Business Quant data shows MNKD's Total Non-Current Liabilities at $798.5 million in Q1 2026, $838.1 million in Q4 2025, and $710.8 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn | 798.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 798.45 Mn |
| Dec 31, 2025 | 838.09 Mn |
| Mar 31, 2024 | 710.79 Mn |
| Dec 31, 2023 | 145.75 Mn |
| Sep 30, 2023 | 572.05 Mn |
| Jun 30, 2023 | 573.85 Mn |
| Mar 31, 2023 | 553.48 Mn |
| Dec 31, 2022 | -55,000.00 |
| Sep 30, 2022 | 531.46 Mn |
| Jun 30, 2022 | 532.77 Mn |
| Mar 31, 2022 | 533.33 Mn |
| Dec 31, 2021 | 525.56 Mn |
| Sep 30, 2021 | 422.61 Mn |
| Jun 30, 2021 | 436.17 Mn |
| Mar 31, 2021 | 488.25 Mn |
| Dec 31, 2020 | 284.88 Mn |
| Sep 30, 2020 | 276.25 Mn |
| Jun 30, 2020 | 277.95 Mn |
| Mar 31, 2020 | 275.00 Mn |
| Dec 31, 2019 | 282.25 Mn |